Myungmoon Pharmaceutical rises 5.06% amid COVID-19 (Camostat) theme surge

On the 11th, the COVID-19 (Camostat) theme showed strength by rising 3.01% compared to the previous day, while Myungmoon Pharmaceutical, a stock attracting attention as a related company, surged 5.06% compared to the previous day. Myungmoon Pharmaceutical is known as a comprehensive pharmaceutical company focused on prescription drugs.

[Graph] Major stock price changes in the COVID-19 (Camostat) theme

According to preliminary data compiled at 13:36, foreign investors are net selling 7,900 shares of Myungmoon Pharmaceutical, while institutions are net buying 1,000 shares.

[Table] Net trading volume by foreign investors and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Myungmoon Pharmaceutical’s quant financial score is 7.4 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (Camostat). This can be interpreted as Myungmoon Pharmaceutical having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, Daewoong Pharmaceutical ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.